Your search for evid returned 33 results

Most men with localized prostate cancer do not die within 15 years, whether or not they receive active surveillance or treatment.

Patients with advanced CKD have not been well-represented in trials evaluating intensive blood pressure control.

The systematic review and meta-analysis included a broad range of patients with and without chronic kidney disease.

Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.

The update reflects advances in hepatitis C management, such as antiviral therapy, increased use of hepatitis C kidney grafts, and treatment of glomerular diseases associated with the virus.

Statin use in prostate cancer is attractive given their proven cardiovascular benefits and favorable toxicity profile, according to investigators.

One study focused on patients with severe lupus nephritis, who are at greatest risk for kidney failure.

Treatment with an SGLT2 inhibitor may help patients with CKD or type 2 diabetes better preserve their kidney function.

Data from real-world practice and a meta-analysis of randomized controlled trials concur.

Among patients with a variety of solid tumors, investigators found favorable associations of immune checkpoint inhibitor therapy with quality of life compared with no immunotherapy use.